

# Sanofi championing efforts in *decarbonizing the patient journey* to be showcased at COP27



Aim to deliver *net zero patient care* through healthcare stakeholder engagement and new way to deliver healthcare services:

- Sanofi sponsored study on telemedicine GHG emissions in Egypt<sup>1</sup>

---

- Study on Dupixent® patient care pathway decarbonization

---

- Product environment life cycle analysis performed on different products such as Dupixent®, Fluzone HD®, Praluent®, Allegra®

---

- Sanofi is driving the engagement with stakeholders such as authorities, payers, service providers, HCP and patients

5%


healthcare systems  
CO<sub>2</sub> contributions  
vs global emissions

45%

is the part of patient  
care pathway in  
healthcare systems  
CO<sub>2</sub> emissions

1. In collaboration with Ain Shams University

# Advancing toward *our net zero target*



Delivering positive impact on communities and the environment

## *Mangroves*

19,500 tCO<sub>2</sub>e/year carbon removed over 20 years

- ✓ Improving biodiversity
- ✓ Additional income from mangrove timber



## *Optimized cookstoves*

52,000 tCO<sub>2</sub>e/year emissions reduction over 15 years

- ✓ Reducing disease related to smoke inhalation
- ✓ Reducing time spent collecting wood



sanofi



ESG  
appendices



Sanofi ESG Q3 *achievements*

## Affordable access



## Global Health Unit #Patients treated

Q2 2022	Q3 2022
<b>Malaria</b> <b>1,693,770</b> <b>10</b> countries	<b>Malaria</b> <b>2,000,995</b> <b>13</b> countries
<b>Tuberculosis</b> <b>76,634</b> <b>13</b> countries	<b>Tuberculosis</b> <b>98,542</b> <b>13</b> countries
<b>NCD</b> <b>85,956</b> <b>21</b> countries	<b>NCD</b> <b>109,934</b> <b>24</b> countries


## Rare disease vials donation

Q2 2022	Q3 2022
<b>1,015</b> patients treated	<b>1,064</b> patients treated
<b>51,370</b> vials donated	<b>76,494</b> vials donated

## Global access plan

Q2 2022	Q3 2022
Pilot completed Blueprint completed	Governance in place and roll-out across all GBU's

## R&amp;D for unmet needs



## Polio eradication

Q2 2022	Q3 2022
<b>27 million IPV doses</b> supplied to UNICEF	<b>38 million IPV doses</b> supplied to UNICEF

## Sleeping sickness elimination

FY 2021 <sup>1</sup>	FY 2022
<b>2 million</b> patients tested for HAT	Data updated annually
<b>805</b> patients treated	

## Pediatric cancer treatment development

Q2 2022	Q3 2022
<b>1</b> asset in pre-clinical assessments	<b>1</b> asset in pre-clinical assessments
<b>1</b> asset in protocol preparation for clinical study	<b>1</b> asset in protocol preparation for clinical study

Sanofi ESG Q3 *achievements*

## Planet care



## Blister-free syringe vaccines

Q4 2021	Q3 2022
29% of blister free syringe vaccines produced	Data updated annually <span style="color: green;">●</span>

## Eco-design

Q2 2022	Q3 2022
5 LCAs completed & 3 in progress	7 LCAs completed & 1 in progress
Eco-design digital solutions project in progress	Eco-design digital solutions project in progress <span style="color: green;">●</span>

## Scope 1 &amp; 2 GHG emissions reduction

Q2 2022	Q3 2022
-27% vs 2019	-28.3% vs 2019 <span style="color: green;">●</span>

## Renewable electricity &amp; eco-car fleet

Q2 2022	Q3 2022
60% renewable electricity	61.4% renewable electricity <span style="color: green;">●</span>
30.4% eco-fleet	32.7% eco-fleet <span style="color: green;">●</span>

## In and beyond the workplace



## Diverse Senior Leadership

Q2 2022	Q3 2022
35.9% of our executives and 41.1% of our senior leaders were women	36.2% of our executives and 41.4% of our senior leaders were women <span style="color: green;">●</span>

## Engagement with communities

Q2 2022	Q3 2022
1,998 volunteers	3,498 volunteers <span style="color: green;">●</span>
12,687 hours	25,265 hours

## From Leaders to Citizens

Q2 2022	Q3 2022
Rollout planned in 2022	Program launched <span style="color: green;">●</span>

Data in YTD unless stated otherwise.

# Sanofi ESG ratings

## Rating agencies



SCORE									
86/100	21.6 Medium risk	69/100	A	Climate Change: A Water: A	B	4.3/5	3.47/5	92%	64/100
New rating	▲ 22	▼ 74/100	= A	▲ A-	= B	▲ 4.2/5	▲ 2.49/5	▲ 90%	▲ 62/100
One of the highest scores across all sectors globally 80 points for its solid fundamentals & strong preparedness opinion of 6 points	12 <sup>th</sup> among 455 pharmaceutical companies	Percentile of 92 within 143 scored companies in the industry	Within the top 6 highest rated pharmaceutical companies	Leading position	1 <sup>st</sup> decile of the 476 companies in the industry	With very high rating across the 3 pillars ESG	Top 5 company	Sanofi's disclosure score well above sector disclosure score (74%)	1 <sup>st</sup> pharmaceutical company out of 57 Score in progress since 2018

▲ Vs previous rating

Scores assigned by the rating agencies are not equivalent.